Navigation Links
endpoint Launches PULSE 2.0 Allowing Clinical Research Teams to Save Additional Time and Money By Rapidly Deploying Studies With Custom Reporting
Date:10/19/2010

SAN FRANCISCO, Oct. 19 /PRNewswire/ -- endpoint Clinical (www.endpointclinical.com), a leader in Integrated Response Technology (IRT) development, today announced the release of PULSE 2.0™. endpoint PULSE is a proprietary platform that enables the configuration of fully validated, custom IRT systems for clinical trials in a fraction of the time required by traditional development. New in PULSE 2.0 is the ability for project managers to create and manage client-specific templates, ensuring that every study endpoint develops automatically contains the client's preferred configurations. PULSE 2.0 also offers enhanced reports and administrative functionality, with a focus on improved control over clinical supplies.

endpoint's PULSE configurable architecture meets Clinical Program Managers' demands for making mid-study changes quickly and easily. endpoint's PULSE platform combines IRT capabilities with pre-validated modules allowing clinical trials to move ahead at a more rapid rate due to project managers having access to the configurable design elements rather than relying on custom development for each change.

"Since launching PULSE in February, we've been compiling a long list of new features and functionality," said Jonathan Dole, co-founder and CEO, endpoint. "PULSE 2.0 is a blend of features our customers are asking for and new tools that enable us to deliver an even more robust IRT system in the same timeframe to which our customers are becoming accustomed."

About endpoint

endpoint is an innovative company dedicated to the development of the leading technology platforms for the life sciences industry. endpoint's founding team has been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma for domestic and global studies with experience across a broad range of therapeutic areas and global implementations. For more information, visit endpoint at www.endpointclinical.com.


'/>"/>
SOURCE endpoint
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
2. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
3. TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis
7. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
8. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
9. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
10. Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
11. R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 According to a new market research report ... Type (Integrated, Standalone), Model (Knowledge-Based), Type (Therapeutic, Diagnostic), User Interactivity (Active, Passive), ... expected to reach USD 1,519.2 Million by 2021 from USD 856.3 Million ... Continue Reading ... ...
(Date:12/7/2016)... , Dec. 7, 2016  Organovo Holdings, Inc. ... biology company focused on delivering scientific and medical ... that Chairman and Chief Executive Officer Keith ... on Wednesday, December 14, 2016 at 1:00 p.m. ... are not yet familiar with the Company, an ...
(Date:12/7/2016)... December 7, 2016 According to ... titled , Global Market Study on Multiplex Detection Immunoassay: North ... , the global multiplex detection immunoassay market is expected to witness ... ... ,      (Logo: ...
Breaking Medicine Technology:
(Date:12/7/2016)... Chicago, IL (PRWEB) , ... December 07, 2016 , ... ... giving back this holiday season by donating a portion of proceeds to two local ... North Chicago Animal Control & Friends is a team of authorized and ...
(Date:12/7/2016)... Dallas, TX (PRWEB) , ... December 07, 2016 ... ... a 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. ... Awards recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken ...
(Date:12/7/2016)... CINCINNATI, Ohio (PRWEB) , ... December 07, 2016 ... ... winner in the 2016 BOC Business Brilliance Awards under the Best New Product ... inception and results achieved through user experience. , BOC Global Events & Training ...
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: ... trial, not a one hour a week showing of hands. “The Road To Restoration” ... begins, “Perhaps you are familiar with the brass ring that you could reach out ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” allows ... that follows. , “Fred Rides a Train” is the creation of published author, ... since her teen years in Michigan. The "Fred, the Dog" series is her first ...
Breaking Medicine News(10 mins):